Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · September 13, 2022

Surgical Resection After Neoadjuvant Durvalumab and Radiation Is Feasible and Safe in Patients With Non–Small Cell Lung Cancer

The Journal of Thoracic and Cardiovascular Surgery

 

Additional Info

The Journal of Thoracic and Cardiovascular Surgery
Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial
J Thorac Cardiovasc Surg 2022 Aug 06;[EPub Ahead of Print], B Lee, N Mynard, A Nasar, J Villena-Vargas, O Chow, S Harrison, B Stiles, J Port, N Altorki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading